Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quadrivalent Influenza Virus Split Vaccine (IMBCAMS)
- Development stage
- Unknown
- Lead developer
- Institute of Medical Biology Chinese Academy of Medical Sciences
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Quadrivalent Influenza Virus Split Vaccine (QIV) is an inactivated, split-virion vaccine developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) in collaboration with Peking Union Medical College. It is designed to prevent seasonal influenza in individuals aged 3 years and older. The vaccine formulation includes purified surface antigens from four influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). By inducing the production of hemagglutination inhibition (HI) antibodies, the vaccine provides protection against the circulating strains of the virus. Clinical development has reached Phase III trials, evaluating safety and immunogenicity through measures such as seroconversion rates and geometric mean titers.
- Other names
- Quadrivalent Influenza Virus Split VaccineIMBCAMS QIVQuadrivalent Influenza Vaccine (split Virion)
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Quadrivalent Influenza Virus Split Vaccine (IMBCAMS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quadrivalent Influenza Virus Split Vaccine (IMBCAMS).